Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

ConditionCongenital Myasthenic Syndrome

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorThe Foundation for Orthopaedics and Regenerative Medicine

About this trial

Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.

Patients must be able to provide informed consent, or have a guardian who does.

Patient must be able to travel to the site of treatment.

Disqualifiers

Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.

Trial design

Design model

Single group

Treatments tested in this trial

AlloEx exosomes
Biological/Vaccine
This is an intranasal treatment of exosomes derived from mesenchymal stem cells.

Treatment groups

20 Participants

are divided into 1 treatment group

Group A: Treatment GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Oxygen Saturation

Time frame

From enrollment to 6 months after treatment

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The Foundation for Orthopaedics and Regenerative Medicine

Lead sponsor

Source ClinicalTrials.gov

Apply now